Results for tag: "Chemotherapy Induced Peripheral Neuropathy"

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of various chemotherapeutic agents used to treat cancer. It is characterized by damage to the peripheral nerves resulting in symptoms such as pain, burning, tingling, and numbness, often in a "glove and stocking" distribution. Within the context of central nervous system (CNS) drugs, CIPN represents a therapeutic area that intersects with neurology and oncology. As a result of the nerve damage caused by chemotherapy, patients may require medication to alleviate symptoms, which can be debilitating and impact quality of life. Management of CIPN includes the use of drugs that typically address neuropathic pain and other neurological symptoms. These CNS drugs include anticonvulsants, antidepressants, opioids, and topical agents, which may be repurposed or optimized for CIPN. The development of specific agents to prevent or treat this condition remains an active area of pharmaceutical research with an aim to improve patient outcomes by directly addressing the underlying mechanisms of nerve damage or by offering symptomatic relief. Several companies in the market that are involved in the development or distribution of treatments for chemotherapy-induced peripheral neuropathy include Pfizer, Eli Lilly and Company, GlaxoSmithKline, Sanofi, and Johnson & Johnson. These companies are typically large pharmaceutical firms with diversified portfolios that include CNS drugs among their therapeutic areas. Show Less Read more